Sign In
Buy MRVI
$6.07
-0.160 (-2.57%)
At Close: Aug 10, 2026
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
04:22pm, Wednesday, 21'st May 2025
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth
Maravai LifeSciences Releases 2024 Sustainability Report
04:05pm, Wednesday, 21'st May 2025
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth
Maravai LifeSciencesReleases 2024 Sustainability Report
04:05pm, Wednesday, 21'st May 2025
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI), is fueling the future of mRNA research — starting with a significant donation to t
NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "
These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results
01:29pm, Tuesday, 13'th May 2025
Maravai LifeSciences Holdings, Inc. MRVI reported mixed results for the first quarter on Monday.
NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "
Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2025 Earnings Call Transcript
12:03am, Tuesday, 13'th May 2025
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Debra Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Becky
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Monday, 12'th May 2025
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.02 per share a year ago
Maravai Lifesciences Reports First Quarter 2025 Financial Results
04:06pm, Monday, 12'th May 2025
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech inn
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "
NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. ("Maravai" or "t
